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Abstract: It is becoming increasingly clear that plants ranging across the plant kingdom produce ani-
onic host defence peptides (AHDPs) with potent activity against a wide variety of human cancers 
cells. In general, this activity involves membrane partitioning by AHDPs, which leads to membranoly-
sis and / or internalization to attack intracellular targets such as DNA. Several models have been pro-
posed to describe these events including: the toroidal pore and Shai-Matsuzaki-Huang mechanisms 
but, in general, the mechanisms underpinning the membrane interactions and anticancer activity of these peptides are 
poorly understood. Plant AHDPs with anticancer activity can be conveniently discussed with reference to two groups: cy-
clotides, which possess cyclic molecules stabilized by cysteine knot motifs, and other ADHPs that adopt extended and ?-
helical conformations. Here, we review research into the anticancer action of these two groups of peptides along with cur-
rent understanding of the mechanisms underpinning this action. 
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INTRODUCTION  
 How plants protected themselves from microbial infec-
tions was long an enigma, given that they lack an adaptive 
immune system, which mediates the defence of humans and 
other vertebrates against these infections [1]. It is now 
known that to offset the lack of specialized mobile immune 
cells possessed by vertebrates, every cell in a plant has the 
facility to launch an effective immune response, which is 
mediated by a multi-layered innate immune system that 
comprises self-surveillance, systemic signalling and chromo-
somal changes acting in combination to protect against mi-
crobial infection and other threats [2, 3]. One layer of this 
immune response involves the production of an arsenal of 
defence peptides and proteins, which includes: pathogenesis-
related (PR)-proteins [4-7], recently redefined as ‘inducible 
defence-related proteins [8, 9], and host defence peptides 
(HDPs), whose primary role is a front-line response to mi-
crobial infections [10-13]. On a structural basis, these HDPs 
can be grouped into the major families: defensins, cyclotides, 
2S albumins, lipid transfer proteins, hevein-like proteins 
knotins, snakins, and glycine-rich proteins [14-21]. Most of 
these peptides are cationic (CHPDs), which facilitates their-
toxicity to target cells [10-21], but it is becoming increas- 
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ingly clear that plants also produce a number of anionic 
HDPs (AHDPs) with toxicity to pests, fungi, viruses, bacte-
ria and cancer cells [13, 22-28]. Currently, the structural / 
functional relationships underpinning the anticancer and 
other biological activities of plant AHDPs are poorly under-
stood although, in most cases, the molecular architecture of 
these peptides has been elucidated [13, 22, 23, 27, 28]. Based 
on their structural characteristics, plant AHDPs with antican-
cer activity can be divided into two groups: cyclotides, 
which possess cyclic molecules stabilized by cysteine knot 
motifs, and other ADHPs that adopt extended and ?-helical 
conformations [22]. Here, we review research into the anti-
cancer action of these two groups of peptides along with 
current understanding of the mechanisms underpinning this 
action and discus their potential to serve as agents in the 
fight against cancers.  
AHDPs THAT ADOPT ?-HELICAL AND EXTENDED 
CONFORMATIONS 
 It has previously been shown that HDPs were present in 
leaf extracts of Cycas revoluta from the Cycadaceae family 
[29] and more recently, Cr-ACP1 (net charge -1), was identi-
fied in seeds of the plant (Table 1) [30]. The peptide was 
found to have selective toxicity towards human cells from 
colon carcinoma (HCT15) and epidermoid cancer (Hp2) with 
IC50 values that were 1.5 mM and 0.6 mM respectively. 
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These results suggested that Cr-ACP1 functioned as a weak 
anticancer agent and mechanisms underpinning the action of 
the peptide against the HCT15 and Hp2 cell lines were in-
vestigated. It appeared that these mechanisms involved intra-
cellular targets, requiring Cr-ACP1 to translocate across the 
membranes of target cancer cells. Consistent with this obser-
vation, studies on the antibacterial activity of the peptide 
suggested that the positive charge carried by its sole lysine 
residue and overall charge distribution played a role in facili-
tating membrane interaction by the peptide. Reinforcing this 
suggestion, theoretical analysis of the peptide showed that it 
had the potential to adopt ?-helical structure with a high 
level of amphiphilicity, indicative of an ability to interact 
with membranes [31, 32]. This molecular architecture is 
adopted by many other AMPs [13, 24, 25] and in particular, 
buforin IIb, which is an ?-helical CAMP that crosses target 
membranes to bind DNA and thereby promote anticancer 
action via the induction of apoptosis [33]. Cr-ACP1 showed 
similarities to the anticancer action of buforin IIb and was 
found to have a strong affinity for DNA, which appeared to 
involve the ability of its charged and polar residues to form a 
stable hydrogen bond network with DNA nucleotides (Fig. 
1). Further studies on Cr-ACP1 led to the suggestion that the 
anticancer action of the peptide utilised anti-proliferative  
 
mechanisms involving the binding of Cr-ACP1 to DNA, 
thereby inducing cell cycle arrest in the G0-G1 phase and the 
initiation of apoptotic mechanisms of cell death [30].  
 Cn-AMP2 (net charge -1) is an antibacterial peptide that 
was first identified in green coconut water, which is the clear 
liquid inside young coconuts from Cocos nucifera of the 
Arecaceae and a popular drink in Tropical Asia and Latin 
America (Table 1) [34]. In a more recent study, Cn-AMP2 
was shown to have selective toxicity towards cancer cells 
from human glioma cell lines (1321N1 and U87MG) with 
IC50 values of 1.25 mM and 1.85 mM respectively [35]. Fur-
ther studies on the peptide lead to the suggestion that, simi-
larly to Cr-ACP1, Cn-AMP2 functioned as a weak antican-
cer agent, which utilised anti-proliferative mechanisms via 
translocation across the membrane to employ intracellular 
sites of action [22, 36, 37]. Strongly supporting this sugges-
tion, Cn-AMP2 demonstrated no membranolytic ability to-
wards any of the cells lines studied as can be seen from Fig. 
2, which clearly shows that cells treated with the peptide 
exhibited no significant morphological differences to control 
cells; no evidence of cell-death, as indicated by a round mor-
phology; and no sign of cell lysis, as witnessed by membrane 
fragmentation or the presence of cellular debris (Fig. 2). In 
 
Table 1. Plants hosting AHDPs with anticancer activity. 
Family Source plant Peptide  Sequence Refs. 
Cycadaceae     
 Cyas revolute Cr-ACP1 AWKLFDDGV [30] 
Arecaceae     
 Cocos nucifera Cn-AMP2 TESYFVFSVGM [106] 
Rubiaceae     
 Oldenlandia affinis Kalata B2 GLPVCGETCFGGTCNTPGCSCTWPICTRD [78] 
  Kalata B13 GLPVCGETCFGGTCNTPGCACDPWPVCTRD [84] 
 Chassalia chartacea  chaC1, GDACGETCFTGICFTAGCSCNPWPTCTRN [66] 
 Palicourea condensata Palicourein CGETCRVIPVCTYSAALGCTCDDRSDGLCKRNGDPTF [65] 
Fabaceae     
 Clitoria ternatea Cliotide T2 GEFLKCGESCVQGECYTPGCSCDWPICKKN [50] 
  Cliotide T3 GLPTCGETCTLGTCYVPDCSCSWPICMKN [50] 
Violaceae     
 Viola abyssinica Vaby D GLPVCGETCFGGTCNTPGCTCDPWPVCTRN [73] 
 Viola odorata cycloviolacin O24 GLPTCGETCFGGTCNTPGCTCDPWPVCTHN [71].  
 Viola philippica, varv H GLPVCCETCFGGTCNTPGCSCETWPVCSRN [72].  
  vitri B GYPICGESCVGGTCNTPGCSCSNPVCTTN [72].  
 Viola yedoensis  Cycloviolacin Y4 GVPCGESCVFIPCITGVIGCSCSSNVCYLN [79] 
  Cycloviolacin Y5 GIPCAESCVWIPCTVTALVGCSCSDKVCYN [79] 
  Cycloviolacin Y1 GGTIFDCGETCFLGTCYTPGCSCGNYGFCYGTN [79] 
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Figure 1. The binding of Cr-ACP1 to DNA. 
Figure 1 was adapted from [30] and shows a binary complex 
formed between Cr-ACP1 and single stranded DNA 5?-CCGGC-3?, 
modelled to represent the strong affinity for DNA by the peptide in 
experimental work. Lateral chains involved in the formation of this 
complex are labelled with dotted lines indicating hydrogen bonds 
and their respective distances given in angstroms. Based on this 
model, DNA binding by the peptide was predicted to involve the 
ability of its charged and polar residues to form a stable hydrogen 
bond network with DNA nucleotides. 
 
 
Figure 2. The effects of Cn-AMP2 on the morphology of cell 
lines 
Figure 2 was adapted from [35] and shows cells of the human 
glioma cell lines, U87MG (Fig. 2A) and 1321N1 (Fig. 2C), along 
with the non-cancerous glial cell line, SVGp12 (Fig. 2E), that had 
been cultured in the presence of Cn-AMP2 at a peptide concentra-
tion of 2 mM. Also shown are cells of the same cell lines that had 
been similarly cultured but in the absence of Cn-AMP2 (Figs. B, D 
and F). It can be clearly seen that samples treated with the peptide 
showed no evidence of cell-death, as indicated by a round morphol-
ogy; and no sign of cell lysis, as witnessed by membrane fragmen-
tation or the presence of cellular debris. All images are at a ?10 
magnification and cell lines were cultured as previously described 
[35].  
 
combination, these data suggested that Cn-AMP2 may be 
cytostatic towards the 1321N1 and U87MG cell lines and, 
although the targets of their anti-proliferative mechanism 
were not investigated, it was speculated that these mecha-
nisms may involve DNA-binding [35].  
 The ability of Cn-AMP2 to interact with cancer cell 
membranes was investigated and it was shown that in the 
presence of lipid mimics of cancer cell membranes, the pep-
tide adopted an extended conformation. In this conformation, 
Cn-AMP2 exhibited a strongly hydrophobic region, formed 
by the C-terminal eight residues of the peptide, 
YFVFSVGM, which was flanked by a short anionic seg-
ment, TES [36, 37]. This residue arrangement endows Cn-
AMP2 with primary amphiphilicity [36, 37], which has been 
reported for other anticancer peptides such as indolicidin [38, 
39] and is known to mediate the ability of these peptides to 
traverse membranes [40]. By analogy to indolicidin, it was 
suggested that the ability of Cn-AMP2 to traverse cancer cell 
membranes may be hydrophobicity driven by a mechanism 
involving the peptide’s C-terminal region [36, 37]. Most 
recently, molecular dynamic simulations were undertaken, 
which strongly supported these suggestions and showed that 
Cn-AMP2 was able to translocate phospholipid assemblies 
that mimicked cancer cell membranes (Fig. 3). These MD 
simulations are depicted in Fig. 3, which shows that the ex-
tended form of Cn-AMP2 is able to approach the surface of a 
target membrane (Fig. 3A) and insert into this membrane 
(Fig. 3B). This insertion event is mediated by the association 
of the peptide’s anionic N-terminal ‘TES’ segment with cati-
onic moieties in the membrane head-group region, such as 
the choline group of DMPC. These electrostatic interactions 
are complemented by penetration of the hydrophobic C-
terminal ‘YFVFSVGM’ segment of Cn-AMP2 into the apo-
lar acyl chain region of the membrane (Fig. 3B). Led by its 
N-terminal segment, the peptide then crosses this acyl chain 
region (Fig. 3C) and exits through the opposing membrane 
leaflet (Fig. 3D) accompanied by no significant overall per-
turbation of the bilayer (Figs. 3A to 3D). It was proposed 
that Cn-AMP2 uses a similar mechanism to enter the human 
glioma cell lines, 1321N1 and U87MG, whereupon the in-
ternalized peptide attacks intracellular targets, such as DNA, 
thereby inhibiting the proliferation and inducing the death of 
these cells (Fig. 3E) [36, 37]. 
AHDPs FROM CYCLOTIDES  
 A number of AHDPs have been identified within the cy-
clotides, which are a major family of cyclic HDPs [41-43] 
with anticancer action (Table 2) and a range of other biologi-
cal activities [41-43], which is generally based on the ability 
of these peptides to interact with target cell membranes [22, 
23, 27]. These peptides are listed in various databases and 
are now known to be ubiquitous in plants [13, 24, 25, 44-46]  
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Figure 3. The passage of Cn-AMP2 across mimics of cancer cell 
membranes 
Figure 3 was adapted from [36] and shows molecular dynamic 
simulations for the interaction of Cn-AMP2 with a model cancer 
cell membrane. In this simulation, Cn-AMP2 (TESYFVFSVGM 
[106]) is in an extended conformation and approaches the surface of 
the membrane (Fig. 3A) and inserts (Fig. 3B). Insertion of the pep-
tide involves association of its anionic N-terminal segment (TES) 
with positively charged moieties in the head-group region of the 
bilayer such as the choline group of DMPC. Complementing these 
electrostatic interactions, the hydrophobic C-terminal segment of 
Cn-AMP2 (YFVFSVGM) penetrates the apolar core region of the 
membrane (Fig. 3B). Led by its N-terminal region, the peptide then 
traverses this core region (Fig. 3C) and emerges through the oppos-
ing leaflet to migrate away from the membrane surface (Fig. 3D) 
with no significant overall perturbation of the bilayer resulting from 
the passage of Cn-AMP2 (Figs. 3A to 3D). Based on the action of 
the peptide against the human glioma cell lines, it was suggested 
that the emergent Cn-AMP2 attacks intracellular targets with the 
result that the ability of these cells to proliferate is inhibited (Fig. 
3E).  
 
with most identified in the Rubiaceae, Violaceae [47, 48] and 
Fabaceae families [49-52] (Table 1) whilst others have been 
recently reported in the Cucurbitaceae [48, 53], Solanaceae 
[54], Poaceae [55] and Apocynaceae families [47]. Kalata 
B2 (net charge -1) is generally taken as the prototypic mem-
ber of AHDPs in cylotides [23, 27] and was first reported in 
the early 1970s when it was identified in Oldenlandia affinis 
of the Rubiaceae (Table 1), which is widely dispersed over 
tropical Africa and is also found in tropical Asia [56-58]. 
The peptide derives its name from the fact that it is a compo-
nent of the uterotonic agent in a medicinal preparation, 
kalata-kalata [58, 59], which is derived from O. affinis and is 
used in parts of Africa to accelerate child birth [60, 61]. Sev-
eral recent studies reported that kalata B2, along with kalata 
B13 (net charge -2; Tables 1 and 2), which is also derived 
from O. affinis, possessed potent anticancer activity. It was 
found that both peptides exhibited IC50 values that were ? 
5.0 μM when directed against cell lines of lymphoma (U-937 
GTB) colorectal cancer (Ht116) and colonadeno carcinoma 
(HT29) that were generally comparable to that of doxorubi-
cin [62, 63], a well-established anticancer drug [64]. Other 
AHDPs from plants of the Rubiaceae, include palicourein 
(net charge -1), from the tropical plant, Palicourea conden-
sate [65], and chaC1 (net charge -1), which was recently 
discovered in Chassalia chartacea [66]. These peptides were 
found to have potent activity against cell lines of cervical 
cancer (HeLa) and acute lymphoblastic leukaemia (CEM-
SS) with IC50 values of 1.5 μM and 9.8 μM, respectively [66, 
67].  
 Several ADHPs with anticancer activity, named cliotides 
CT2 and CT3 (net charges of -1), were recently reported in 
the tropical plant, Clitoria ternatea, of the Fabaceae family 
(Table 1), and were shown to be effective against HeLa cells 
(IC50 = 0.6 μM and 8.0 μM respectively) [50]. More recently, 
cliotide CT2 was found to have activity against human non-
small lung cancer cells (A549; IC50 = 7.6 μM) and an A549-
derived paclitaxel-resistant sub-line (A549/taxol; IC50 = 7.9 
μM). However, in the case of A549/taxol cells this IC50 was 
reduced to 1.62 μM when these cells were exposed to 50:50 
ratios of cliotide CT2 and paclitaxel [68], which is another 
well-established anticancer drug [69]. These observations 
indicated a synergistic action between paclitaxel and cliotide 
CT2 and showed that the peptide was able to chemosensitize 
cancer cells to conventional anticancer drugs [68]. A similar 
chemosensitizing ability has been demonstrated for a number 
of other cyclotides in combination with doxorubicin and it 
was suggested that this synergistic interaction resulted from 
the ability of cyclotides to disrupt cellular membranes, 
thereby allowed increased uptake of doxorubicin into drug 
resistant cells [70].  
 A number of ADHPs have been identified in plants of the 
Violaceae family (Table 1), including cycloviolacin O24 (net 
charge -2) from Viola odorata along with varv H and vitri B 
(net charges -1 in both cases) from Viola philippica, which 
are both common horticultural plants [71, 72]. These pep-
tides possessed IC50 values, which ranged between 6.2 μM 
and 16 μM and were found to possess activity against cell 
lines of human gliomablastoma cells (U251) and CEM-SS 
cells [67, 72]. Strong activity against these latter cancer cells 
was also reported for a trio of AHDPs (IC50 values 1.7 μM to 
4.5 μM ) named cycloviolacins Y1 (net charge -2), Y4 (net 
charge -1) and Y5 (net charge -1), which were identified in 
Viola yedoensis (Wild Chinese violet), an important herb in 
Chinese medicine [67]. In contrast, vaby D (net charge -1) 
was isolated from Viola abyssinica which grows in extreme 
habitats and altitudes in the Ethiopian Highlands. The pep-
tide was found to have a broad spectrum of anticancer activ-
ity with IC50 values ranging between 3 μM to 47 μM when 
directed against a variety of cancers, including hepatocellular 
carcinoma cells (BEL-7402), and breast carcinoma (MDA-
MB-231) [42, 73]. More recently, the mechanisms underpin-
ning the activity of the peptide to U-937 GTB lymphoma 
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cells was investigated, which suggested that, in addition to 
targeting the membranes of these cells, the peptide may be 
taken up to inflict damage on DNA and other internal targets 
[74].  
 It is generally accepted that the ability of cyclotides to 
interact with membranes is facilitated by the rigid molecular 
topology possessed by the vast majority of these peptides, 
which is characterized by a cystine knot motif embedded in a 
macrocyclic backbone (Fig. 4) [41-43]. This topology pro-
vides a molecular framework, which includes six backbone 
loops that define hydrophilic and hydrophobic surface re-
gions (Fig. 4) [41-43], thereby giving the tertiary structure of 
these molecules amphiphilic characteristics that allow parti-
tioning into biological bilayers [75, 76]. However, based on 
structural differences in their molecular framework, cy-
clotides can be divided into a number of groups [41, 42], 
including two major subfamilies, generally known as the 
Möbius and bracelet peptides (Fig. 4) [15, 77], and a much 
smaller group termed chimeric cyclotides [65]. The Möbius 
and bracelet subfamilies have fundamentally different mo-
lecular architectures that are primarily distinguished by the 
presence of a conserved proline residue in cis conformation 
in loop 5 of the former subfamily, causing a 180° twist in the 
loop, which is not seen in the latter subfamily [15, 77]. Most 
of the cyclotide aHPDs with anticancer activity have been 
shown to belong to either the Möbius or the bracelet sub-
families (Table 2) with typical examples including: kalata B2 
[78] and cycloviolacin Y4 [79] respectively (Fig. 2). How-
ever, the molecular architectures of chimeric cyclotides in-
clude structural characteristics of both the Möbius and brace-
let subfamilies [65] and include: cycloviolacin Y1 [79] and 
palicourein [65] (Table 2).  
 The differing topologies of Möbius and bracelet cy-
clotides lead to differences in their modes of membrane in-
teraction, which primarily relates the clustering pattern of 
apolar residues that form the hydrophobic surface patches 
possessed by these peptides. These residues and patches 
make the major hydrophobic contribution to the membrane 
partitioning of cyclotides and are mainly centred on loops 5 
and 6 of Möbius peptides and loops 2 and 3 of bracelet pep-
tides [80], as shown for kalata B2 and cycloviolacin Y4 in 
Fig. 4. However, the electrostatic contribution to the mem-
brane partitioning of both subfamilies appears to involve 
hydrophilic patches formed primarily by the presence of 
positively charged residues in loops 5 and 6 of these peptides 
(Fig. 4) [80, 81]. Examples of this residue distribution can be 
seen in most cyclotide anticancer AHPDs, including: kalata 
B2, which has an arginine residue in loop 6 [78], and cy-
cloviolacin Y5, which has a lysine residue in this loop [67]. 
Although anionic overall, these AHPDs are effectively func-
tioning as CHDPs by utilising their cationic residues as ma-
jor promoters of the electrostatic contribution to their mem-
brane partitioning [27]. However, other cyclotide AHPDs 
with anticancer activity, such as cycloviolacin Y4 and cy-
cloviolacin O24, lack cationic residues and the only anionic 
residue in loops 5 and 6 of these peptides is a single aspartic 
acid residue in loop 5 of cycloviolacin O24 [71, 79]. In these 
cases, it has been proposed that the strongly hydrophobic 
Table 2. Major AHDPs with anticancer activity. 
Cyclotides Charge Anticancer activity Refs 
Cn-AMP2 -1 Glioma (1321N1 and U87MG) [106] 
Cr-ACP1 -1 Colon carcinoma (HCT15) and epidermoid cancer (Hp2) [30] 
Kalata B2a -1 Lymphoma (U-937 GTB) colorectal cancer (Ht116) and colonadeno carcinoma (HT29) [62, 63] 
Kalata B13 a -2 Lymphoma (U-937 GTB) [63] 
cycloviolacin O24a -2 Acute lymphoblastic leukaemia (CEM-SS) [67] 
Vaby Da -1 Lung cancer (A549), gastric carcinoma (BGC-823), hepatocellular carcinoma (BEL-7402), prostate cancer 
(DU145), breast carcinoma (MDA-MB-231), gliomablastoma (U251) and lymphoma (U-937 GTB) 
[42, 73] 
Chac1a -1 Cervical cancer (HeLa) [66] 
Cliotide T2a -1 Cervical cancer (HeLa) and lung cancer (A549)  [50, 68] 
Cliotide T3a -1 Cervical cancer (HeLa) [50] 
varv Hb -1 Gliomablastoma (U251) [72]. 
vitri Bb -1 Gliomablastoma (U251) [72]. 
Cycloviolacin Y4b -1 Acute lymphoblastic leukaemia (CEM-SS) [67] 
Cycloviolacin Y5b -1 Acute lymphoblastic leukaemia (CEM-SS) [67] 
Cycloviolacin Y1c -2 Acute lymphoblastic leukaemia (CEM-SS) [67] 
Palicoureinc -1 Acute lymphoblastic leukaemia (CEM-SS) [67] 
Table 2 shows AHDPs from plants and their target cancer cells. Membership of the Möbius subfamily of cyclotides is denoted by a and membership of the bracelet subfamily is 
indicated by b. Chimeric cyclotides, which include structural characteristics of both the and bracelet subfamilies, are denoted by c. Details of the characterisation of these AHDPs is 
supplied in the associated references. 
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nature of loops 5 and 6 would most likely be the major driv-
ing force behind the membrane partitioning of these peptides 
[67]. Currently, the role of negatively charged residues in the 
membrane interactions of not only cyclotide AHDPs but also 
other members of this peptide family is generally unclear 
[27]. 
 Major investigation into the interactions of cylotide 
ADHPs with naturally occurring cancer cell membranes do 
not appear to have been yet undertaken and most of the un-
derstanding in relation to these interactions derives from 
studies on models and mimics of these membranes [62, 75, 
76, 81, 82]. However, these studies have shed some light on 
the role of negatively charged residues in cyclotides and 
have established that an essential requirement for the mem-
brane interactions appears to be the possession of a con-
served glutamate residue in loop 1 of their molecular frame-
work [83]. This residues participates in a structurally impor-
tant network of hydrogen bonds to the adjacent loop 3 and is 
depicted in the primary and tertiary structures of kalata B2 
and cycloviolacin Y4 in Fig. 2 [83]. The sole exception to 
this requirement appears to be kalata B12 (net charge-2), 
which is another of the ADHPs found in O. affinis [84] and 
has an aspartate residue substituted in the otherwise con-
served glutamate position [83]. As is believed for ADHPs in 
general [22, 23, 27], their counterparts within the cylotides 
do not appear to require protein receptors to facilitate their 
membrane interactions [85] although the universality of this 
belief is in question [38, 86]. Most recently, kalata B2 and a 
number of other AHDPs within the cyclotides were found to 
show a strong preference for phosphatidyl ethanolamine (PE) 
in their membrane interactions, which led to the suggestion 
that PE may serve as a lipid receptor for these peptides [62, 
81, 82]. The conserved glutamate of kalata B2, and other 
AHDPs, appeared to play a primary role in their PE-binding 
mechanisms through ionic interactions between the residue’s 
carboxylate side-chain and the ammonium group of the lipid. 
These interactions were stabilised by non-specific hydropho-
bic associations between hydrophobic patches on the surface 
of kalata B2 and lipid acyl chains forming the apolar bilayer 
core region [62, 81, 82]. To investigate this suggestion, here, 
we undertook molecular dynamic simulations of kalata B2 
interacting with a bilayer constructed from DMPE (Fig. 5). 
These simulations predicted that the peptide possessed high 
affinity for these bilayers and bound strongly to the lipid 
head-group region of the membrane, which would support 
the suggested receptor role for the lipid [62, 81, 82]. These 
simulations further predicted that PE-binding by kalata B2 
involved electrostatic and hydrogen-bond interactions be-
tween residues in loops 2, 3 and 6 of the peptide and phos-
 
Figure 4. Structural characteristics of kalata B2 and cycloviolacin Y4. 
Figure 4 was adapted from [67, 80] and shows the tertiary structures of kalata B2 (Fig. 4A) and cycloviolacin Y4 (Fig. 4C), which are Mo-
bius and bracelet cyclotides, respectively. The former group of peptides is distinguished by possession of a cis-proline peptide bond in loop 
5. The core of these structures is the ‘cysteine knot’ motif, which can be seen is formed by conserved cysteine residues, which are indicated 
as I – VI in Figs. 4A and 4C, along with Figs. 4B and 4D, which shows the primary structures of these peptides. In Figs. 4B and 4D, the 
sequences of the backbone loops between conserved cysteine residues are indicated and annotated as L1 to L6. In Figs. 4A and C, it can be 
seen that these backbone loops define the general surface topology of kalata B2 and cycloviolacin Y4 but for convenience, only some loops 
are indicated. The topology of these two peptides differs in relation to their hydrophobic surface patches, which are centred on L5 and L6 in 
kalata B2, and on L2 and L3 in cycloviolacin Y4. In both cases, hydrophobic patches are shown in blue whilst hydrophilic and charged re-
gions are indicated in red.  
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phate and ammonium moieties within the head-group region 
of the bilayer (Fig. 5), which is also in good general agree-
ment with previous work [62, 81, 82]. However, our simula-
tions also predicted that the conserved glutamate of PE-
bound kalata B2 was distal from the membrane surface and 
was not involved in this binding mechanism (Fig. 5), con-
trasting to previous experimental work [62, 81, 82]. One 
likely explanation for this apparent difference would seem to 
be that other components and / or properties of the model 
membranes used in these latter studies play a role in stabiliz-
ing the glutamate-mediated orientation of kalata B2 when 
binding to the PE head-group and clearly, these membrane 
components and properties are not replicated in the relatively 
simple lipid system used in our molecular dynamic simula-
tions.  
 Although it is generally accepted that the anticancer ac-
tivity of AHDPs from cyclotides involves membrane interac-
tion, the mechanisms underpinning these actions are poorly 
understood [15, 41]. In response, there have been a number 
of studies on kalata B2 [62, 75, 76, 81, 82], which suggested 
that the peptide may utilise a variant of the toroidal pore 
mechanism [62, 82], one of the most commonly used 
mechanisms of membrane perturbation used by HDPs [87]. 
Experimental data, which strongly favoured this suggestion, 
led to a model for the membrane interactions of kalata B2 
and other ADHPs, which is shown in Fig. 6 [82]. According 
to this model, monomers or oligomers of kalata B2 approach 
the membrane surface (Fig. 6A) and specifically bind PE 
head-groups whilst concomitantly interacting non-
specifically with the lipid’s acyl chains (Fig. 6B). It has pre-
viously been shown that kalata B2 is able to form tetramers 
and octamers in aqueous solution [88] although more recent 
studies have suggested that these oligomers are unlikely to 
be the functional units involved in pore formation by the 
peptide [89]. This model then proposes that the progressive 
aggregation of kalata B2 molecules on the membrane sur-
face, either as monomers or loosely packed oligomers, im-
poses a positive curvature strain by increasing the distance 
between membrane lipid head-groups, an effect usually de-
scribed as membrane thinning. Once the localized concentra-
tion of kalata B2 molecules on the membrane surface reaches 
a threshold value, they insert into the bilayer whilst remain-
ing in contact with the PE head-group. This action leads to 
cavitation of the membrane surface and ultimately, the for-
mation of toroidal pores that are lined by lipid head-groups 
and hydrophilic surfaces of the participating cyclotide mole-
cules (Fig. 6C). This process continues until high concentra-
tions of kalata B2 are reached when lipids are extracted from 
the membrane, which results in solubilisation and ultimately, 
disintegration of the bilayer (Fig. 6D) [62, 75, 76, 81, 82]. It 
 
Figure 5. The binding of kalata B2 to a PE bilayer 
Figure 5 shows a molecular dynamic simulation of kalata B2 interacting with a bilayer formed from DMPE. In this simulation, the peptide 
approaches the membrane surface (Fig. 5A) and binds to the lipid-head-group regions with high affinity for these bilayers (Fig. 5B), which 
would support the suggested receptor role for the lipid [62, 81, 82]. Fig. 5C shows a close up of PE-bound kalata B2, which predicts that this 
binding involves electrostatic and hydrogen-bond interactions between ammonium moieties within the head-group region of the bilayer and 
residues in loops 2 (residues F10 and T13), loop 3 (residues T16 and P17) and loop 6 (residues D29 and P3) of the peptide. These simula-
tions also show that the conserved glutamate residues (E7 in loop 2) of PE-bound kalata B2 is distal from the membrane surface (Indicated 
with an arrow in Fig. 5C) and is not involved in this binding mechanism, contrasting to previous observations [62, 81, 82].  
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has been also suggested that ADHPs from cyclotides may 
use other mechanisms of membranolysis [22] and, as de-
scribed above, more recent studies on the anticancer activity 
of vaby D have suggested that the peptide may be able to 
attack internal targets of cancer cells [74]. This ability would 
be consistent with use of the Shai, Huang and Matsazuki 
model of membrane perturbation [87], which appears to be 
used by some non-plant AHDPs [27, 90] and includes the 
toroidal pore mechanism but allows for the internalization of 
peptides via transient pore formation [87].  
DISCUSSION 
 In this review, over a dozen AHDPs with anticancer ac-
tivity have been described from sources across the plant 
kingdom, ranging from garden plants such as violets of the 
Violaceae to tropical plants such as palm trees of the Are-
caceae (Table 1). In general, these peptides are effective 
against a wide variety of human cancers cells, including 
some of the deadlier forms of the condition such as glioblas-
toma (Table 2). As to why these AHDPs possess the capacity 
for anticancer activity is unclear as, self-evidently, this ca-
pacity has no relevance to plant survival [85]. However, it 
has been suggested that this anticancer activity may result 
from the general ability of these peptides to interact with 
membranes [86], which appears to have evolved to kill mi-
croorganisms in line with the role of most HDPs as endoge-
nous antimicrobials [39]. This review has shown that the 
anticancer actions used by plant AHPDs are based on mem-
brane interaction, which at least in some cases, appears to 
involve the use of PE as a lipid receptor (Fig. 4). This would 
appear to be one of the first instances of such use by these 
AHDPs although a similar use of the lipid has been reported 
for several non-plant AHDPs [91-93], including some with 
anticancer activity such as maximin H5 from amphibians 
[36]. This review has also shown that the membrane parti-
tioning of plant AHDPs with anticancer activity leads to 
membranolysis and / or internalization to attack intracellular 
targets such as DNA and several models have been proposed 
to describe these events (Figs. 2 and 5). These models in-
clude: the toroidal pore and Shai-Matsuzaki-Huang mecha-
nisms but, in general, the mechanisms underpinning the 
membrane interactions and anticancer activity of AHPDs 
from plants are poorly understood. The membrane interac-
tive structures used by these peptides are diverse and include 
 
Figure 6. A model for the membrane interaction of kalata B2. 
Figure 6 was adapted from [82] and shows a model for the membrane interactions of kalata B2 and other ADHPs. According to this model, 
monomers or oligomers of these cyclotides approach the membrane surface (Figure 6A) and specifically bind PE head-groups whilst inter-
acting non-specifically with the lipid’s acyl chains (Fig. 6B). The progressive aggregation of kalata B2 molecules on the membrane surface, 
either as monomers or loosely packed oligomers, imposes a positive curvature strain by increasing the distance between membrane lipid 
head-groups. Once the localized concentration of peptides on the membrane surface reaches a threshold value, they insert into the bilayer 
whilst remaining in contact with the PE head-group. This action leads to cavitation of the membrane surface and ultimately, the formation of 
toroidal pores that are lined by lipid head-groups and hydrophilic surfaces of the participating cyclotide molecules (Fig. 6C). This process 
continues until high concentrations of kalata B2 are reached when lipids are extracted from the membrane, which results in solubilisation and 
ultimately, disintegration of the bilayer (Fig. 6D). 
Anionic Host Defence Peptides from the Plant Kingdom Protein & Peptide Letters, 2016, Vol. 23, No. 8    9 
extended conformations and ?-helical architecture although 
the majority are based on cysteine stabilized scaffolds, which 
are by far the most common structures found in plant HDPs 
[19]. A few of the AHDPs described here have net charges 
of -2 although most have a net charge of -1, which would 
seem to suggest that low levels of anionicity are required for 
their membrane interactions and anticancer activity. In rela-
tion to the roles of specific anionic residues in this activity, it 
has been established that conserved glutamate residues in 
cyclotides play important structural roles in the membrane 
interactions of these peptides as well as helping to facilitate 
binding to PE receptors. A structural role has also been sug-
gested for aspartate residues in the case of ?-helical HDPs 
such as Cr-ACP1 where they tend to occupy positions that 
are i ± 3 or i ± 4 relative to basic residues. It has been sug-
gested that this structural positioning may promote helix 
formation via salt bridging and thereby serve as a strategy to 
stabilise ?-helical structure [38]. 
 However, in the vast majority of cases, detailed descrip-
tions of the role played by anionic residues in the anticancer 
action of AHDPs from plants is lacking.  
 In their native form, there are a number of issues attached 
to the use of the AHDPs described here as therapeutically 
viable anticancer agents. In the case of Cr-ACP1 and Cn-
AMP2, the millimolar levels of these peptides required to 
elicit an anticancer response is obviously prohibitive to such 
use. However, it has been observed that AHDPs such as Cn-
AMP2 that are devoid of cationic residues possess an advan-
tage over CHDPs with anticancer action whose possession of 
lysine and arginine residues makes them highly susceptible 
to degradation by human proteases [94, 95]. This suggests 
that the intrinsic properties of Cr-ACP1 and similar AHDPs, 
such as cycloviolacin Y4 and cycloviolacin O24, which also 
lack cationic residues, may endow them with anticancer 
mechanisms that are not available to their cationic counter-
parts making them attractive propositions as candidates for 
therapeutic development. For example, these compounds 
may be effective against cancer cells with multiple drug re-
sistance that has rendered CHDPs ineffective when directed 
against these cells.  
 In their native form most AHDPs from cyclotides have 
anticancer activity in the low micromolar range, which is 
approaching therapeutically desirable levels but many of 
these peptides are non-selective for cancer cells and possess 
potent haemolytic action, such as kalata B2 and cliotide T3 
[22]. However, other AHDPs from cyclotides with antican-
cer action such as kalata B13 and vaby D show no evidence 
of haemolytic action and may therefore be suitable for de-
velopment in the treatment of cancerous conditions [22]. 
Indeed, vaby D would seem to be a good candidate for such 
development given that the peptide shows by far the broadest 
range of anticancer activity of the cyclotide AHDPs so far 
tested in this capacity (Table 1). Moreover, many AHDPs 
from this plant family are known but have yet to be tested for 
anticancer activity [22] whilst others are increasingly being 
identified such as the recently reported Viphi H (net charge -
1) from Viola philippica of the Violaceae [96]. Indeed, it has 
been predicted the total number of cyclotides in the 
Rubiaceae alone exceeds 50,000, which would seem to 
indicate that there are large numbers of AHDPs within the 
cyclotides with the potential for anticancer activity yet to be 
identified [47].  
 This review has shown that a number of AHDPs have the 
potential to act as templates in the development of novel 
compounds with the ability to kill a range of cancers. In this 
capacity, as shown by this review, AHDPs from cyclotides 
are by far the most researched and it is becoming increas-
ingly clear that their anticancer potential may be achieved 
through progress in deriving synthetic versions of these pep-
tides [22]. The high plasticity and tolerance to substitution of 
the cyclotide scaffold is now well established and several 
studies have clearly shown that bioactive peptide sequences 
can be efficiently grafted into these scaffold for a variety of 
therapeutic purposes, including the production of compounds 
with anticancer capacity [48, 97]. For example, PE shows the 
potential to serve as a biomarker for many malignancies [98] 
and it has been proposed that derivatives of PE-binding cy-
clotides may be suitable for development as agents in tumour 
imaging and anticancer therapeutics [75, 76, 81, 99, 100]. As 
another example, it may be possible to optimise the mem-
brane-permeabilizing ability of cyclotides through scaffold 
modification to efficiently synergise the action of established 
anticancer drugs, as described above for cliotide CT2 and 
paclitaxel [68]. Proof-of-concept for such work was recently 
demonstrated when a grafted cyclotide, showed activity 
against growth factors involved in angiogenesis [101]; it is 
well-established that tumor growth is usually associated with 
unregulated angiogenesis [102]. As further proof-of-concept, 
more recently, work, which was patented [103], 
demonstrated that engineered cyclotides were cytotoxic to 
cancer cells through activation of the p53 tumor suppressor 
pathway, which is commonly inactivated by these cells to 
promote survival [104].  
 In summary, here we have presented the first major re-
view of research into AHDPs from plants with anticancer 
activity. It is clear from this review that although this re-
search is its infancy, these peptides have the potential to 
serve as therapeutically useful anticancer agents. However, 
to achieve this potential a much greater understanding of 
factors such as their pharmacokinetics and modes of antican-
cer action needs to be acquired. Nonetheless, given this un-
derstanding, plant AHDPs may prove to be a major untapped 
source of answers to the rapidly increasing global problem of 
cancer [105]. 
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